Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

James Bailey

Internal Medicine Tulsa, OK Medical Doctor

NPI 1699750349 CMS profile 303410

6585 S Yale Ave, Ste 1150, Tulsa, OK 74136

Open in the dashboard

General payments

$5,667

377 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, James Bailey of Tulsa, OK is reported in the CMS Open Payments database as having received $5,667 across 377 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $14 1
2022 General $38 2
2021 General $1,164 75
2020 General $1,343 92
2019 General $3,108 207

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Bailey
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Bailey were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Bailey Internal Medicine median Middle half National median
2019 $3,108 $159 $48–$570 $163
2020 $1,343 $119 $33–$402 $114
2021 $1,164 $135 $37–$521 $132
2022 $38 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $14 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Pharmaceuticals, Inc $458 25 payments
  2. Merck Sharp & Dohme Corporation $435 44 payments
  3. Amgen Inc. $391 22 payments
  4. Novartis Pharmaceuticals Corporation $358 25 payments
  5. Novo Nordisk Inc $343 20 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $297 22 payments
  7. AstraZeneca Pharmaceuticals LP $269 10 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $256 16 payments
  9. Lilly USA, LLC $247 20 payments
  10. Pfizer Inc. $222 18 payments
  11. Other $2,392 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,667 377 payments
Products named General payments · program years 2019–2024
  1. XARELTO $458 25 payments
  2. JANUVIA $406 41 payments
  3. STEGLATRO $393 40 payments
  4. ENTRESTO $358 25 payments
  5. XIFAXAN $332 21 payments
  6. BELSOMRA $272 27 payments
  7. Prolia $232 13 payments
  8. EVENITY $215 12 payments
  9. INVOKANA $201 15 payments
  10. JARDIANCE $182 14 payments
  11. Other $5,982 415 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record